About us Pricing ContactSubscribe

B

Brian Druker

Cancer Institute (WIA)ORCID https://orcid.org/0000-0001-8331-8206

h-index

—

Publications

—

Citations

—

i10-index

—

Impact (2-yr)

—

Top Publications

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Nature Medicine19963,643 citationsFirst authorCorresponding

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Journal of Clinical Oncology20032,287 citations

Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors

Journal of Pharmacology and Experimental Therapeutics20001,280 citations

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Cancer Cell20091,234 citations

<i>In vitro</i> Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

Cancer Research20051,030 citations

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

Leukemia2002901 citations

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

Leukemia2009843 citations

Brian Druker · Scinovex